Related Experiment Video

Updated: Aug 4, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Pharmacoeconomic considerations in assessing and selecting congestive heart failure therapies

Emile Levy1, Pierre Levy

  • 1Laboratory of Health Organization Economics and Management, Paris Dauphine University, Paris, France. emile.levy@dauphine.fr

Pharmacoeconomics
|October 31, 2002
PubMed

Insights

Angiotensin-converting enzyme (ACE) inhibitors are vital for managing congestive heart failure (CHF), reducing mortality and healthcare costs. Further comparative studies are needed to optimize drug selection and treatment strategies for better patient outcomes.

Area of Science:

  • Cardiology
  • Pharmacoeconomics

Background:

  • Congestive heart failure (CHF) incidence is rising due to an aging population.
  • Mortality rates from coronary heart disease have declined, but CHF management remains critical.
  • Angiotensin-converting enzyme (ACE) inhibitors have significantly advanced CHF treatment.

Purpose of the Study:

  • To review the role of ACE inhibitors in CHF management.
  • To analyze the cost-effectiveness of ACE inhibitors and other CHF therapies.
  • To discuss current trends and future directions in CHF treatment strategies.

Main Methods:

  • Review of clinical studies on ACE inhibitors in symptomatic CHF and post-infarction left ventricular dysfunction.
  • Analysis of cost-effectiveness studies comparing ACE inhibitors with standard treatments (digoxin, diuretics).
  • Evaluation of current treatment trends, including first-line therapy with ACE inhibitors and beta-blockers versus polypharmacy.

Main Results:

  • ACE inhibitors reduce cardiovascular mortality and prevent CHF progression.
  • ACE inhibitors are cost-saving or cost-effective compared to digoxin and diuretics.
  • Cost savings are documented for beta-blockers; implantable devices require further assessment.

Conclusions:

  • A combined approach integrating clinical trial evidence and cost-effectiveness analyses is essential for CHF management.
  • Further comparative data is needed to guide drug selection within classes.
  • Institutional purchasers should conduct analyses to match drugs to patient profiles and budgets.

More Related Videos

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

Clinical Application of Phase Angle and BIVA Z-Score Analyses in Patients Admitted to an Emergency Department with Acute Heart Failure04:05

Clinical Application of Phase Angle and BIVA Z-Score Analyses in Patients Admitted to an Emergency Department with Acute Heart Failure

Published on: June 30, 2023

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.